After Cantor Fitzgerald and Oppenheimer gave Healthequity (NASDAQ: HQY) a Buy rating last month, the company received another Buy, this time from Barrington. Analyst Alexander Paris maintained a Buy rating on Healthequity today and set a price target of $100. The company’s shares closed yesterday at $73.57.
Paris wrote:
“We are reiterating our OUTPERFORM investment rating and price target of $100, suggesting more than 36% upside from current levels. HQY plans to hold an in NYC. Company Description HealthEquity, Inc. engages in the provision of healthcare saving solutions. Its products include healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives.”
According to TipRanks.com, Paris is a 4-star analyst with an average return of 7.2% and a 47.6% success rate. Paris covers the Services sector, focusing on stocks such as Adtalem Global Education Inc, American Public Education, and Strategic Education Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Healthequity with a $87.33 average price target, representing a 18.7% upside. In a report issued on March 18, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $90 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $101.58 and a one-year low of $50.29. Currently, Healthequity has an average volume of 871.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HealthEquity, Inc. engages in the provision of healthcare saving solutions. Its products include healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.
